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Despite existing vaccination strategies targeting TRP-2, its function is not yet fully understood. TRP-2 is an
enzyme involved in melanin biosynthesis and therefore discussed as a differentiation antigen. However, in mice
Trp-2 was shown to be expressed in melanocyte stem cells of the hair follicle and therefore also considered as
an indicator of stemness. A proper understanding of the TRP-2 function is crucial, considering a vaccination
targeting cells with stemness properties would be highly effective in contrast to a therapy targeting
differentiated melanoma cells. Analysing over 200 melanomas including primaries, partly matched metastases
and patients’ cell cultures we show that TRP-2 is correlated with Melan A expression and decreases with tumor
progression. In mice it is expressed in differentiated melanocytes as well as in stem cells. Furthermore, we
identify a TRP-2 negative, proliferative, hypoxia related cell subpopulation which is significantly associated with
tumor thickness and diseases progression. Patients with a higher percentage of those cells have a less
favourable tumor specific survival. Our findings underline that TRP-2 is a differentiation antigen, highlighting the
importance to combine TRP-2 vaccination with other strategies targeting the aggressive undifferentiated hypoxia
related subpopulation.
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Melanoma is a highly aggressive neoplasm. Patients with distant
metastases often face very poor prognosis, with a median survival
rate of approximately 9 months, and with less than 10% of patients
surviving beyond 5 years [1,2]. Tumor growth and spread is
known to be regulated by the crosstalk between tumor cells and
stroma including immune cells. Moreover spontaneous tumor
regression has been shown in melanoma and demonstrated to be
regulated by the immune system. The ability of the immune
system to recognize melanoma cells is based on the presence of
immunogenic antigens capable of triggering a specific immune
response. A continuous search for tumor antigens, which could be
used to direct the human immune system against cancer lead to the
discovery of several families of key-cancer-related molecules [3–7].Between these tyrosinase related protein 2 (TRP-2; also known as
dopachrome tautomerase; DCT) represents to date a major target
of immunotherapy for melanoma.
TRP-2 is a membrane-bound melanosomal enzyme involved in
melanin biosynthesis also known as a melanoma differentiation
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tissue and brain [8]. TRP-2 was identified by screening a tumor
cDNA library with a T cell line exhibiting an in vivo antitumor
activity. This finding demonstrated the immunogenicity of TRP-2
and to date several epitopes of this protein have been described to be
recognized by specific cytotoxic T lymphocytes in humans. Based on
these findings, TRP-2 represents a good target for immunotherapeu-
tic treatment of melanoma [9–11].
Although several vaccination strategies targeting TRP-2 have been
developed so far [12–15], its expression in melanoma tissues is not yet
fundamentally investigated. It has been reported that TRP-2 is neural
crest specific and only expressed in melanocytes, in the pigment
epithelium of the retina and in the brain [8]. Of major interest is that
TRP-2 has been described to be hypoxia related [16].
In this project we investigated the expression of TRP-2 in over
200 melanoma biopsies and cell cultures from primary melanomas
and metastasis. Moreover, we characterized the subpopulation
of melanoma cells expressing TRP-2. Trp-2 (Dct) is a marker of
melanocytic lineage and in mice its expression in the bulge region
of the hair follicle identifies stem cell population [17]. However,
Trp-2 (Dct) is expressed throughout the melanocytic lineage
including not only melanocyte stem cells, which are c-Kit negative
but also melanoblasts and differentiated melanocytes, which express
c-Kit marker.
Taken together our findings illustrate that TRP-2 is a melanoma
differentiation antigen and not a stem cell marker.
Furthermore, we identified an aggressive, proliferative TRP-2-
negative subpopulation in primary melanoma, which significantly
increases with tumor progression. Interestingly, the presence of this
subpopulation in primary melanoma is associated with Breslow
tumor thickness, hypoxia and indicates a less favourable tumor
specific survival. This is in contradiction with the idea that TRP-2
might label the melanocyte stem cell population, while it is believed
that stem cells are associated with more aggressive behaviour and
less differentiation in many tumors. Our findings suggest that a
TRP-2 vaccination would target the more differentiated melanoma
cells. This approach should be ideally combined with other
therapies able to target the aggressive hypoxia related undiffer-
entiated subpopulation.Materials and Methods
Tumor Specimens
All analyses involving human melanoma tissue were performed
in accordance with the ethical committee in canton Zurich.
Immunohistochemistry was performed on three different tissue
microarrays (TMAs) representing a total of 81 primary melanomas,
59 melanoma metastasis and 65 melanoma patients’ derived cell
cultures. The TMAs partly included matched tumor samples from
primary tumors, metastases and cell cultures. Totally, 9 triplets
consisting of primary melanoma, metastases and cell cultures, 5
pairs including primary melanoma and metastases and 25 pairs of
melanoma tissue (9 primary and 16 metastases) matched with cell
cultures were analysed. One TMA consisted of primary melanomas
(Breslow tumor thickness N1 mm) with available clinical data and
follow up information about the patients included. Detailed
clinical information of this TMA has been reported in a previous
study [18].The melanoma cells cultures were derived from surgical specimen
of melanoma patients included in a life bio bank project. Written
informed consent was approved by the local IRB (EK647 and
EK800). TMA containing melanoma cell cultures and melanoma
tissue were constructed as previously described [19].
Approval for the use of melanoma TMAs and melanoma
metastases was obtained from the official ethical authorities of the
Canton Zurich (StV 16–2007).
Mice
All animal experiments were performed in accordance with Swiss
law and have been approved by the veterinary authorities of Zurich.
Immunohistochemistry
For the mouse experiments: skin samples were fixed with 4%
formaldehyde and frozen in OCT compound. For immunohisto-
chemistry, sections were stained as previously described [20]. Anti-
Dct (rabbit, ab74073, Abcam) was used.
Sections of 2 μm from a tissue TMA were stained with antibodies
against Melan A, Hif-1α, TRP-2 and Mib-1. The immunohisto-
chemical staining for all antigens was performed on automated
staining systems Melan A, TRP-2/Mib-1 on Ventana Bench Mark,
Ventana Medical Systems, Tucson, AZ, USA and Hif-1α on Bond
Refine, Vision BioSystems Ltd, Newcastle Upon Tyne, UK. The
following antibodies were used: Hif-1α clone mgc3 (Abcam
Limited), dilution 1:400; Melan A clone A103 (DAKO A/S),
dilution 1:30; Mib-1 clone 30–9 (Ventana-Roche), prediluted.
Evaluation of TRP-2, Melan A and Hif-1α Expression
To determine the expression frequencies of TRP-2, the hot spot
of a tumor sample was chosen and the percentage of positive cells
per 100 melanoma cells was recorded. In addition, using a co-
staining for Mib-1, four different combinations of positive and
negative cells for Mib-1 and TRP-2 were recorded. For the
evaluation of Melan A and Hif-1α a semi quantitative scoring
system was applied following the German immunohistochemical
scoring (GIS) system in which the final immunoreactive score
equaled the product of the percentage of positive cells times the
highest staining intensity. The percentage of positive cells was
graded as follows: 0: negative; 1: up to 10% positive cells; 2: 11% to
50%; 3: 51% to 90%; and 4: N90%. Staining intensity was graded
as follows: 0: negative; 1: weakly positive; 2: moderately positive
and 3: strongly positive [21]. All stainings were evaluated by an
experienced pathologist (D.L.).
Hypoxia Treatment
Cells were cultured in a Modular Incubator Chamber (MIC-101,
Billups-Rothenberg inc.), flushed with 20 liters/minute (flow meter;
RMA-23-SSV; Dwyer) with certified premixed gas composed of 1%
O2 , 5% CO2 and 94% N2 (CARBAGAS, Switzerland). The O2
concentration inside the chamber was measured with an oxygen
sensor (VTI-122, Disposable Polarographic Oxygen Cell; 100122,
Vascular Technology). The hypoxia chamber was placed in an
incubater at 37 °C for 72 hours before RNA isolation.
qRT-PCR
Total RNA was extracted from primary melanoma cell cultures
using TRIzol according to manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). Total RNA was used for cDNA synthesis using
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USA) according to the supplied protocols. Gene expression was
quantified using the FastStart Universal SYBR Green Master (ROX;
04913914001, Roche Basel, Switzerland) and the Viia7 system from
Applied Biosystems. The primers for DCT and RPL28 were
purchased from Qiagen (Venlo, The Netherlands).
Statistical Analyses
Correlations between TRP-2, Melan A, Mib-1 and Hif-1α in
melanoma were analyzed using Spearman’s rank correlation. TRP-2,
TRP-2/Mib-1, Hif-1α and Melan A were compared between
different patient groups using the Mann–Whitney test. Wilcoxon
signed ranks test was used to analyse the expression of TRP-2, Melan
A and Hif-1α in matched tumor samples. Survival differences
between groups were calculated by a log rank test. The Cox-regression
analysis was applied for analysis of the association between tumor
TRP-2/Mib-1 expression and tumor-specific survival.
p-values below 0.05 were considered as significant. IBM SPSS
Statistics 20 (SPSS Inc., Chicago, IL) was used for statistical analyses.
GraphPad Prism 5 was used for Boxplots and Kaplan-Meier curve.Figure 1. Graphs with statistical analysis of TRP-2, TRP-2 negative/Mib
cultures (mean and standard deviation).Results
TRP-2, Melan A and Mib-1 Expression in Primary
Melanoma and Metastases
We found a correlation between expression of TRP-2 and the
melanoma differentiation anitgen Melan A in primary melanomas
(p = 0.0001; Spearman’s correlation coefficient 0,6) as well as in
metastases (p = 0.0001; Spearman’s correlation coefficient 0,6).
Importantly, there was a significant more frequent TRP-2
expression in primary melanomas compared to metastases (p =
0.009; Figure 1A). Thirty-six of 81 (44%) primary melanomas and
14 of 59 (24%) metastases showed TRP-2 expression in over 10% of
melanoma cells. In 9 out of 12 matched samples a decrease in TRP-2
expression was detected in the metastases compared to the primaries;
in 2 out of 12 samples an increase of TRP-2 in the metastases
compared to the primaries was detected and in 1 out of 12 the
expression of TRP-2 was absent in the primary as well as in the
metastases. However these results are statistically not significant (p =
0.08) due to the low number of samples and the weak expression of
TRP-2 in the metastases (Figure 1B). In addition, we found also a-1 positive andMelan A in primary melanomas, metastases and cell
Figure 2. Co-staining of Mib-1/TRP-2 and Melan A staining in primary melanoma and corresponding metastasis (A-F). Moderate TRP-2
expression in over 50 percent of primary melanoma cells (A x100; C x400) and negativity in themetastasis (B x100; D x400). Greater extent
of proliferating TRP-2 negative cells (arrow) in the metastasis (D x400) in comparison to the primary melanoma (C x400). Primary
melanoma with strong Melan A expression in over 50% of tumor cells (E x100) and less than 10% in the metastasis (arrow; F x100).
Overview of melanoma cell culture array with abcence of TRP-2 expression in most melanoma patient's cell cultures (H x10). Cell culture
with TRP-2 negative proliferating cells (arrow; G x400).
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Figure 3. Primary melanoma with strong Hif-1α expression in over
50% of tumor cells (A x200). Identical primary melanoma with co-
staining for Mib-1/TRP-2 without TRP-2 expression (B x200).
Proliferating TRP-2 negative tumor cells (arrow). Two different
melanoma patient's cell lines (M010817 and M000921) under
normoxic (blue) and hypoxic (red) conditions: Significant down-
regulation of TRP-2 in the hypoxia treated samples (C). Fluores-
cence labelling for Dct in mouse skin (D-F): Dct expression in
melanocyte stem cells of the hair follicle bulge (E) as well as in
melanocytes of the hair follicle bulb (F).
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to their matched primary tumor tissue (p = 0.01; Figure 1C).
These findings indicate the survival benefit of TRP-2 negative cells
in cell culture.
Using our newly developed co-staining of Mib-1 and TRP2, we
analyzed the proliferating (MIB-1 positive) melanoma cells depend-
ing on their TRP-2 expression in primary melanoma, and metastases
(Figure 2A-D). In melanoma metastases, proliferating TRP-2
negative cells were significantly more frequent compared to the
primaries (p = 0.01; Figure 1D), whereas non-proliferating TRP-2
positive cells were significantly less frequent in melanoma metastases
compared to the primaries (p = 0.01). For the subgroups, which
were either negative or positive for both markers, we found no
significant difference between primary melanomas and metastases.
Interestingly the percentage of TRP-2−/Mib-1+ cells significantly
correlated with Breslow tumor thickness in the patient group with
Breslow tumor thickness over 1 mm (p = 0.048; Spearman’s
correlation coefficient 0,3). Furthermore, these cells were signifi-
cantly correlated with Hif-1α expression (p = 0.03; Spearman’s
correlation coefficient 0,3) and therefore with hypoxic condition in
primary melanoma. In addition patients who had less than 15% of
TRP-2−/Mib-1+ in their primary melanoma had statistically an
approaching significance for a better tumor specific survival (p =
0.05; Figure 1E).
TRP-2, Melan A and Mib-1 Expression in Melanoma
Tissue Compared to Melanoma Cell Cultures
Melanoma patients’ cell cultures expressed significantly less Melan
A than primary melanomas (p = 0.001) or metastases (p = 0.001;
Figure 1 F). In addition TRP-2 was significantly less expressed in
cell cultures if compared to primaries (p = 0.001) or to metastases
(p = 0.02; Figure 1A).
Hypoxia Inducible Factor 1α (Hif-1α) and TRP-2 Expression
Hif-1α expression was significantly higher in melanoma metastases
(p = 0.04) and cell cultures (p = 0.0001) when compared to primary
melanomas (Figure 1G).
Analysing all melanoma samples primary melanomas, metastases
and melanoma cell cultures we found a significant correlation
between Hif-1α expression and the the presence of TRP-2−/Mib-1+
cells (p = 0.002; Spearman’s correlation coefficient 0,2) as well as
with proliferation (Mib-1) alone (p = 0.01 Spearman’s correlation
coefficient 0,2). However, analysing separately the different groups,
only a significant correlation between Hif-1α expression and the
presence of TRP-2−/Mib-1+ cells in melanoma patient’s cell cultures
persisted (p = 0.01; Spearman’s correlation coefficient 0,3).
We found no significant correlation between Hif-1α, and TRP-2
expression neither in primary melanoma, melanoma metastases nor
melanoma cell cultures as expected by cell line experiments.
Hypoxia is Downregulating TRP-2 in Primary Human
Melanoma Cell Cultures
We treated primary human melanoma cell cultures with
hypoxia for 72 hours and subsequently performed qRT-PCR for
TRP-2 (Figure 3C). The results show a significant downregulation
(5.8- resp. 7.6-fold) of TRP-2 in the hypoxia treated samples
compared to untreated control cells, supporting the observed
correlation of Hif-1α expression and the the presence of TRP-2−/
Mib-1+ cells.TRP-2 Fluorescence Labeling in the Hair Follicle in the
Mouse Skin
As previously shown [17], Dct expression in the hair follicle bulge
labels melanocyte stem cells. Fluorescence labelling of Trp-2 (Dct)
showed positivity for Dct in the melanocytes in the hair bulb region,
thereby showing that Trp-2 expression is not restricted to the stem
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melanocytic differentiation antigen and not a stem cell marker.
Discussion
In this study, we characterize TRP2 as a melanoma differentiation
antigen without evidence to be a stem cell marker. Our data are
consistent with a model that an aggressive proliferative TRP-2-
negative subpopulation exists in primary melanoma, which signifi-
cantly increases with tumor progression.
In the past years a major effort was to define new tumor targets
for immunotherapeutic purposes. Ideally these targets should be
stably and specifically expressed in the tumor and able to trigger an
immune response.
TRP-2 is an immunogenic enzyme involved in the melanin
synthesis and considered as a melanoma differentiation marker but
also as a melanocyte stem cell marker. There is evidence that cancer
stem cells are involved in the tumor progression and dissemination,
which includes a series of distinct steps that together comprise the
“invasion–metastasis cascade” [22]. Therefore, a therapy that targets
cancer stem cells could be highly effective if not curative. Accordingly,
the role of TRP-2 in melanoma as a stem cell or differentiation marker
is a relevant issue for therapeutical purposes. In mice, we show that
Trp2 (Dct) is a differentiation antigen and not a stem cell marker
demonstrated by the fact that the population of melanoblasts/
melanocytes express Trp-2 as well as melanocyte stem cells, located in
the bulge region of the hair follicle (Figure 3D-F). In order to study
the expression of TRP-2 (DCT) in humans, we analysed primary and
metastatic melanomas as well as patients’ derived primary melanoma
cell cultures. We could demonstrate that TRP-2 expression is
significantly correlated with expression of the melanoma differenti-
ation antigen Melan A in primary melanomas, and melanoma
metastases. These data suggest that TRP-2 expression is rather
correlated with the differentiation degree of melanocytes as indicated
by the co-expression with Melan A. In addition, there is a significant
loss of TRP-2 expression with tumor progression. These results
underline that TRP-2 is a differentiation antigen and not a stem cell
marker also in human melanoma.
From molecular profiling studies it is established that progression
of tumors, including malignant melanomas, is associated with an
accumulation of new genetic hits [23]. It is therefore reasonable that
differentiation antigens are lost with tumor progression. Interestingly
despite several TRP-2 vaccination studies [12–15], TRP-2 expression
has not been studied yet in human melanoma. Our study is the first
report on TRP-2 expression in over 200 melanomas and melanoma
cell cultures.
According to our data TRP-2 negative cells are considered an
aggressive subpopulation, which has a survival benefit and which is
highly proliferative. Interestingly, this TRP-2 negative/Mib-1 positive
subpopulation is significantly associated with Breslow tumor
thickness. Furthermore, patients with more than 15 percent of
TRP-2 negative/Mib-1 positive cells in their primary melanoma,
approached significance for a less favourable tumor specific survival.
The course of their disease was more aggressive with earlier
development of metastases and death (Figure 1E).
Remarkably, the presence of the TRP-2 negative/Mib-1 positive
subpopulation is significantly hypoxia related. TRP-2 and other genes
involved in the pigment production pathway, including Melan A, are
transcriptional targets of the transcription factor microphthalmia-
associated transcription factor (MITF). Hoek et al. and others havedeveloped a model of tumor progression, in which melanoma cells are
switching between two cell phenotypes of proliferation and invasion.
MITF and many of its target genes, including TRP-2, were shown to
be downregulated in the dedifferentiated invasive phenotype cells
compared to the more melanocytic proliferative phenotype cells.
Our experiments show a clear downregulation by TRP-2 by
hypoxia, supporting recent studies which show that hypoxia, through
Hif-1α is leading to a downregulation of melanocytic markers like
MITF and its targets and therefore causing a dedifferentiation of the
melanoma cells with increased invasive potential [24,25]. Hypoxia
plays an important role in the differentiation process of cells [26,27]
as well as in tumor progression [28]. Therefore, our finding in
melanoma that the TRP-2 negative/Mib-1 positive cells are hypoxia
related is of relevance as this indicates that this subpopulation of cells
would not be targeted by vaccination. Several chemotherapies target
hypoxic cells and moreover hypoxic specific therapies have been
developed (ie TH302) [29].
In the field of tumor immunology, a successful strategy implies
polyvalent immunization and synergistic combination of chemother-
apies and vaccination. Taken together our results demonstrate TRP-2
as a good differentiation marker highlighting the importance to
combine TRP-2 vaccination with other strategies targeting the
aggressive undifferentiated hypoxia related subpopulation.
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